Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS. (May 2023) - Garcia-Manero, G.; Bachiashvili, K.; Amin, H.; Traer, E.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Cripe, L.; Berdeja, J.; Griffiths, E.; Mohan, S.; Vachhani, P.; et al.